Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Podolin

Cardiovascular Disease San Francisco, CA Medical Doctor

NPI 1295876860 CMS profile 331457

1 Shrader St, Suite 600, San Francisco, CA 94117

Open in the dashboard

General payments

$19,585

846 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Podolin of San Francisco, CA is reported in the CMS Open Payments database as having received $19,585 across 846 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,811 110
2024 General $3,466 121
2023 General $3,177 145
2022 General $3,258 143
2021 General $2,809 131
2020 General $1,982 94
2019 General $2,081 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Podolin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Richard Podolin were reported at $2,811. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Richard Podolin Cardiovascular Disease median Middle half National median
2019 $2,081 $450 $127–$1,392 $163
2020 $1,982 $242 $77–$751 $114
2021 $2,809 $335 $101–$1,037 $132
2022 $3,258 $395 $121–$1,211 $149
2023 $3,177 $443 $136–$1,283 $160
2024 $3,466 $450 $136–$1,323 $164
2025 $2,811 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,655 75 payments
  2. Amgen Inc. $1,585 71 payments
  3. Abbott Laboratories $1,396 23 payments
  4. AstraZeneca Pharmaceuticals LP $1,381 65 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,331 62 payments
  6. E.R. Squibb & Sons, L.L.C. $1,294 66 payments
  7. Esperion Therapeutics, Inc. $919 38 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $902 41 payments
  9. Janssen Pharmaceuticals, Inc $880 45 payments
  10. Pfizer Inc. $776 37 payments
  11. Other $7,466 323 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,554 836 payments
  2. Travel and Lodging $1,006 7 payments
  3. Education $24 3 payments
Products named General payments · program years 2019–2025
  1. Repatha $1,365 62 payments
  2. ENTRESTO $1,032 50 payments
  3. AVEIR $998 8 payments
  4. JARDIANCE $976 47 payments
  5. NEXLETOL $919 38 payments
  6. LifeVest $902 41 payments
  7. XARELTO $880 45 payments
  8. Ozempic $725 39 payments
  9. RYBELSUS $701 38 payments
  10. VERQUVO $679 26 payments
  11. Other $13,328 595 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

3,178

Median for Cardiology: 2,533

Drug cost

$2,339,436

Median for Cardiology: $485,213

Branded share of claims

29.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 50 $1,525,734
Eliquis Apixaban Brand 320 $425,885
Xarelto Rivaroxaban Brand 72 $103,191
Entresto Sacubitril/Valsartan Brand 53 $88,890
Multaq Dronedarone Hcl Brand 20 $39,183
Repatha Sureclick Evolocumab Brand 38 $38,231
Jardiance Empagliflozin Brand 23 $37,249
Praluent Pen Alirocumab Brand 11 $9,010
Dofetilide Generic 31 $7,599
Livalo Pitavastatin Calcium Brand 11 $7,270

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$162,352

Of which drugs: $407

Medicare patients

371

Average age 79

Services billed

1,962

188 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 45%
Arthritis 44%
Ischemic heart disease 37%
Diabetes 33%
Heart failure 32%
Chronic kidney disease 30%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 23 92 $367

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$189 38 —
JARDIANCE
$188 23 —
CAMZYOS
$164 — —
FARXIGA
$163 — —
LEQVIO
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

846 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record